Treatment of Malignant Tumors With Antigen Peptide-specific DC-CTL Cells and Decitabine

Inclusion Criteria: 1. Male or female patients aged 18-70 (including 18 and 70 years old); 2. Diagnosed as malignant tumor by pathological and histological examination; 3. Patients with ECOG score \<2 and estimated survival time\>3 months; 4. Patients need to receive systemic combined chemotherapy according to their condition; other treatments such as surgery, radiotherapy, and targeted therapy are excluded; 5. The previous treatment-related toxicity of the patient 2 weeks before the enrollment had returned to \<1 grade at the time of enrollment (except for low-grade toxicity such as alopecia and peripheral neuritis); 6. The patient's intravenous access is unobstructed, which can meet the needs of intravenous drip; 7. The patient voluntarily participates and signs the informed consent form, and follows the research treatment plan and visit plan; Exclusion Criteria: * Any one of the exclusion criteria shall not be included in the group: 1. Patients used high-dose hormones within 1 week before enrollment (except for patients using inhaled hormones) 2. People with severe autoimmune diseases, immunodeficiency diseases or severe allergies; 3. Patients treated with other cellular immune products (DC, T, NK, and CAR-T, etc.); 4. The patient had uncontrollable infections within 4 weeks before enrollment; 5. Active HBV DNA\>1000copy/mL/C hepatitis (anti-HCV positive, HCV RNA positive), HIV positive, syphilis positive; 6. The patient participated in other clinical studies within 6 weeks before enrollment; 7. Patients suffering from mental illness; 8. The patient has drug abuse/addiction and medical, psychological or social conditions that may interfere with research or have an impact on the evaluation of research results; 9. The patient has alcohol dependence; 10. Women who are pregnant (positive urine/blood pregnancy studies) or breastfeeding; men or women who have a pregnancy plan within the past year; patients cannot be guaranteed to take effective contraceptive measures during the study period; 11. According to the judgment of the investigator, the patient has other unsuitable conditions for enrollment.